|
|
|
| Solutions For Accelerated Pharmaceutical Development | Article | By David K. Lyon, Ph.D. and Conrad Roten, Ph.D., Lonza | Uncover an integrated service package designed to simplify and accelerate the development pathway, even for APIs with challenging properties such as low aqueous solubility and poor bioavailability. |
|
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | For biotechs meeting with current and potential investors, says Edward Ahn, CEO, Medipost Inc., “it should be about demonstrating your business continuity more than anything else.” Investors know, he says, “any supply chain may be fragile.” Indeed, Ahn’s organization has put in place an intriguing business model to address such concerns. It includes owning part of a CDMO. | |
|
|
The Trends Shaping Clinical Trial Supply | By Priyanka Bhendale, MarketsandMarkets | Decentralized trials and biotech product needs are changing how investigational products reach patients. New market research reveals trends. |
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
|
|
|
|
|
|
|
The Story Behind 20 Years Of Success | Eurofins PSS Insourcing Solutions | Beth DiPaolo, SVP, recounts how the company started with a client who needed a tailored service model to meet a scope of work they would never outsource, laying the foundation for a client-focused culture. |
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
